Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015

J. Erin Staples, MD; Joseph A. Bocchini Jr., MD; Lorry Rubin, MD; Marc Fischer, MD

Disclosures

Morbidity and Mortality Weekly Report. 2015;64(23):647-650. 

In This Article

Yellow Fever Vaccine Booster Dose Safety Data

Serious adverse events, yellow fever vaccine–associated viscerotropic disease (a severe illness similar to wild-type disease), and yellow fever vaccine-associated neurologic disease were considered critical risks to assess the need for yellow fever vaccine booster doses.[7]

Serious Adverse Events

Nine observational studies provided data on serious adverse events for 333 million distributed doses of yellow fever vaccine.[3] Overall, 1,255 persons were reported to have a serious adverse event after yellow fever vaccination. For most (84%) persons, it was unknown if the adverse event occurred after a primary or booster dose of the vaccine. Of the 201 persons with a serious adverse event where dose type was known, 14 (7%) of the adverse events occurred after a booster dose of vaccine.

Viscerotropic Disease

Eight observational studies provided data on viscerotropic disease for 437 million distributed doses of yellow fever vaccine.[3] A total of 72 persons had yellow fever vaccine–associated viscerotropic disease. Of the 31 persons where dose type was known, one (3%) had viscerotropic disease after receiving a booster dose of the vaccine; no laboratory testing to assess vaccine causality was performed for that case.

Neurologic Disease

Eight observational studies provided neurologic disease data for approximately 462 million distributed doses of yellow fever vaccine.[3] A total of 218 persons had yellow fever vaccine–associated neurologic disease. Of the 110 persons where dose type was known, three (3%) persons reported neurologic disease after receiving a booster dose of the vaccine.

processing....